Aptar Pharma Announces Capacity Expansion in North America

Aptar Pharma, part of AptarGroup, Inc., has announced the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site. This investment aims to help Aptar meet the growing prescription and consumer healthcare customer demand for proprietary drug delivery systems in North America.
 
Manufacturing began at Aptar Congers in 2002 with a cleanroom and the production of Aptar Pharma’s VP3 pumps, and today the site manufactures a wide range of proprietary drug delivery products for nasal and injectable delivery routes. Manufacturing capabilities at the Congers facility will be further expanded to offer even more product solutions and increased production capacity to Aptar Pharma customers in North America.

Expanded Production for Proprietary Drug Delivery Systems

To support increasing patient demand for systemic nasal delivery, Aptar Pharma is significantly expanding the manufacturing capacity of its proprietary Unidose (UDS) Nasal Spray Systems via the addition of molds and assembly lines in cleanroom manufacturing settings, with the additional capacity planned to come online in Q4 2024.
 
To meet increased customer demand in the region for nasal saline solutions, Aptar Pharma is installing an assembly line at the Aptar Congers facility to further expand manufacturing of its bag-on-vale (BOV) technology. This new environmentally controlled good manufacturing practice (GMP) production area is planned to be fully operational by early 2025.
 
As demand continues to grow in North America for child-resistant packaging for nasal decongestant sprays, Aptar Pharma’s plans also include a cleanroom extension at the site for its Child-Resistant Senior-Friendly (CRSF) closure solutions to increase manufacturing capacity to supply customers locally.

Global Expansion Plan

The new capacity will be housed in the building extension at the existing Aptar Congers site and is planned to be completed by the end of 2024, with the goal to significantly boost capacity across several Aptar Pharma product lines.
 
The building extension adds an additional 28,500 sq. ft. of manufacturing footprint to enhance warehousing, cleanroom and manufacturing capabilities at the site.
 
Aptar Pharma’s expansion in North America is part of the company’s overall global expansion plan, which includes a robust injectables expansion program in France, and new manufacturing facilities in Suzhou, China and Mumbai, India. This newly expanded Congers facility is the company’s direct response to continuing customer demand in the region, and supports Aptar’s “local for local” strategy.
 
As part of the global injectables expansion program, a portion of the expanded facility has been dedicated to Aptar Pharma’s ETFE PremiumCoat film-coated stoppers manufacturing, including on-site molding and trimming, which will be performed in a new ISO-7 cleanroom, while finishing and automated vision inspection will continue to be performed in an ISO-5 cleanroom. PremiumCoat production at Aptar Congers, on track to be ready for commercialization in early 2025, is covered by the same Drug Master File (DMF) as the Aptar Granville and Aptar Brécey manufacturing sites in France.
 
“Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines,” commented Gael Touya, President, Aptar Pharma. “This expansion is a key step in the next phase of our global expansion program, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients.”